With the conclusion of Q4 2022 results reporting period, we look back at the overall 2022 financial performance for European Pharma under our coverage and how they fared against consensus estimates, as well as the outlook for 2023.
European Pharma: Top Picks as Growth Slows; New Launches and Core Products are Key
09 March 2023
Want to learn more? Download the Report.
Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
Public Policy ResearchIdentify opportunity and risks driven by public policy.
Forensic Accounting ResearchUnderstand implications of public company financial reporting.
Health Care REITs Poised for Healthy Returns
The aging US population and increasing healthcare expenditures...Read more